Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 119 participants.

Also called NCT05266586

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 119 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05266586
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05266586. Randomized; quadruple masking; primary purpose treatment. Start 2022-03-09 (actual); primary completion 2022-08-12 (actual). Results posted on 2024-07-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
Acronym
ROSE2
Condition
Dyslipidemias
Condition
High Cholesterol
Condition
Hypercholesterolemia
Intervention (Drug)
Obicetrapib
Intervention (Drug)
Ezetimibe 10mg
Intervention (Other)
Obicetrapib placebo
Intervention (Other)
Ezetimibe placebo
Lead sponsor
NewAmsterdam Pharma (class: industry)

Record details

Record id
cardio:ct-nct05266586
Content hash
0a296a75131f8de4a2dc6212b6ff150207dcbf2a2e45a5c40e43d7d1b8f688d9